Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate, Using 3D-CRT or Intensity-Modulated Radiotherapy

NCT01444820 is registered in ClinicalTrials.gov with Sir Mortimer B. Davis - Jewish General Hospital as lead sponsor.

NCT NCT01444820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01444820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate, Using 3D-CRT or Intensity-Modulated Radiotherapy
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 31, 2012
Completion date
January 31, 2026
Enrollment
329 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer